Economic evaluation has become increasingly important to inform decision makers about how to allocate scare resources, especially with the increasing health care expenditures, the rapid introduction of new medical technologies and the extending role of economic evaluations in health care decision making. Medical innovations are nowadays introduced and diffused in a controlled manner and have to respond to economic criteria. We aim to evaluate the economic value of innovative medical technologies in order to help public and private decision makers to efficiently allocate scare health resources. Our multidisciplinary team provides services, analyses and expertise for several academic, public and private decision makers to efficiently allocate scare health resources, by estimating the relative efficiency of therapeutic and diagnostic interventions (e.g. cost-effectiveness analyses) and by using more innovative methods (e.g. discrete choice experiments, risk-sharing models).